BRAIN Biotech AG Appoints New Executive Vice President for Enzyme Products Business

BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, has appointed Johan Jansen-Storbacka as Executive Vice President of the BRAINBiocatalysts' enzyme products business, effective September 1, 2025. This appointment signals the company's strategic focus on strengthening its enzyme and fermentation operations amid growing global demand for sustainable industrial processes.

Jansen-Storbacka brings more than 20 years of experience in biotechnology with extensive expertise in enzyme applications spanning industrial processes, animal nutrition, and home care. He holds an M.Sc. in Engineering and Management as well as an MBA, making him well-suited to lead the company's enzyme products division during a period of increased focus on biological solutions across multiple industries.

The new executive will oversee a team of approximately 140 employees and manage fermentation facilities in the UK along with production sites in continental Europe and the United States. His role involves driving the BRAIN Biotech Group's strategy to enhance its enzyme and fermentation business while ensuring closer integration of research and production activities across the organization. This integrated approach is crucial for maintaining competitiveness in the rapidly evolving biotechnology sector.

Adriaan Moelker, CEO of BRAIN Biotech, emphasized the significance of this appointment, stating that Jansen-Storbacka's broad industry background will be valuable as the company continues to serve diverse end markets. His international experience and leadership skills position him to effectively manage the global operations detailed on the company's website at https://www.brain-biotech-group.com/.

Jansen-Storbacka succeeds Rod Sears-Black, who retired on January 1, 2025. During the interim period, CEO Adriaan Moelker temporarily held the role and will now fully dedicate his time to leading the BRAIN Biotech Group. The transition comes as the company, which generated revenue of €54.6 million with approximately 300 employees in the 2023/24 fiscal year, continues to expand its footprint in specialty enzymes and microbial production strains.

The appointment is particularly significant given the growing importance of enzyme technology in developing more sustainable products and efficient industrial processes. As industries worldwide seek biological alternatives to traditional chemical processes, companies like BRAIN Biotech play a critical role in advancing the biologization of industry. The company's work in developing scalable bioprocesses for economic production of specialty enzymes addresses key challenges in sustainable manufacturing.

BRAIN Biotech AG, listed on the Frankfurt Stock Exchange since February 9, 2016, operates through two main business segments: BRAINBiocatalysts for development, production, and distribution of specialty enzymes, microorganisms, and ingredients, and BRAINBioIncubator for research-intensive development projects and pharmaceuticals. The company's continued investment in leadership talent reflects the strategic importance of the enzyme products business to its overall growth strategy in the rapidly expanding bioeconomy.